Currently, there is no standard of care for patients with relapsed or refractory multiple myeloma (RRMM) who are triple‐class exposed (to IMiDs, PIs, and anti‐CD38 MoABs), with previous evidence showing that this population is treated with at least 336 different regimens that comprise 40 different compounds[4], frequently consisting of continuous triplet therapies [5]. This evidence concerns the gene CD38 and plasma cell myeloma.